Description |
Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells[1][2].
|
In Vitro |
Ingenol 3,20-dibenzoate (0-10000 nM; 4 hours) enhanced NK cells (stimulated by A549 cells and H1299 cells) degranulation[2]. Ingenol 3,20-dibenzoate (0.001-10 μg/ml) dose dependently promoted UT-7/EPO cell proliferation with an EC50 of 0.27 μg/ml (485 nM)[3].
|
In Vivo |
Ingenol 3,20-dibenzoate (20 μg/mouse; i.p.; on days 3, 7, and 11) lessens the anemia induced by 5-fluorouracil in an in vivo mouse model[3]. Animal Model: Male C57BL/6 mice (8–12 weeks old)[3] Dosage: 20 μg/mouse Administration: I.p.; On days 3, 7, and 11 Result: Severity of 5-FU–induced anemia was lessened by IDB treatment on days 12 and 20.
|
Density | 1.32 g/cm3 |
Boiling Point | 697ºC at 760 mmHg |
Flash Point | 221.6ºC |
Exact Mass | 556.24600 |
PSA | 110.13000 |
LogP | 4.54460 |